Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole IM for Agitation in Schizophrenia
NCT00036127Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Apr 2002
- Primary completion
- Jan 2003
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aripiprazole in schizophrenia (6 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Positive and Negative Syndrome Scale - Excited Component at 2 hours. Started Apr 2002; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00036127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036127.